TUXEDO:西妥昔单抗联合放化疗治疗肌层浸润性膀胱癌的I/II期试验
TUXEDO是一项在六家英国医院开展的前瞻性单臂开放标签I/II期试验,评估西妥昔单抗联合标准化疗放疗治疗肌层浸润性膀胱癌的可行性与初步疗效。I期显示联合治疗可行且安全,所有患者完成计划放疗;II期可评估患者中25例在治疗后3个月达到确认的局部控制(77%,95%CI:58-90)。研究因入组缓慢而提前终止。
要点
- I期显示西妥昔单抗联合放化疗可行且安全,所有患者完成计划放疗,无延迟或减量。
- II期可评估的30例患者中,25例在治疗后3个月达到确认的局部控制(77%,95%CI:58-90)。
- 试验期间共发生18例严重不良事件,8例患者因不良反应停用西妥昔单抗,研究因入组缓慢终止。
核心结论
- I期数据表明,在放化疗基础上加用西妥昔单抗是可行且安全的。
- II期数据的探索性分析提供了考虑对该方案进行进一步临床评估的证据。
研究设计与样本
- TUXEDO是一项前瞻性、单臂、开放标签的I/II期试验,在六家英国医院开展。
- 共招募33例患者,I期7例,II期26例;II期中有3例随后被判定不符合条件且未接受试验治疗。
- 入组患者为T2-4aN0M0尿路上皮癌且体力状态(PS)为0-1,允许既往新辅助治疗。
- 西妥昔单抗给药方案:第-1周第1天初始负荷剂量400mg/m2,随后每周给予250mg/m2,共7次。
- 放疗方案为64Gy/32F,第1天给予丝裂霉素C(12g/m2),第1-5天和第22-26天给予5-氟尿嘧啶(500mg/m2/天)。
主要发现
- 患者中位年龄为70.1岁(范围60.6-75.1),20例PS为0,27例为男性,26例已接受新辅助化疗。
- I期所有患者均完成计划放疗,无延迟或剂量减少。
- II期可评估的30例患者中,25例在治疗后3个月达到确认的局部控制(77%,95%CI:58-90)。
- 试验期间共发生18例严重不良事件;8例患者因不良反应停用西妥昔单抗。
- 研究因入组缓慢而终止。
关键数值与推荐
- I期主要结局为对放疗完成情况及治疗期间毒性反应的影响。
- II期主要结局为治疗后3个月的局部控制。
- II期可评估患者中,治疗后3个月确认局部控制率为77%(95%CI:58-90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因入组缓慢而终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess feasibility and preliminary efficacy of adding cetuximab to standard chemoradiotherapy for muscle-invasive bladder cancer. PATIENTS AND METHODS: TUXEDO was a prospective, single-arm, open-label, phase I/II trial conducted in six UK hospitals. Cetuximab was administered with an initial loading dose of 400mg/m2 on day 1 of week -1, and then 7-weekly doses of 250mg/m2 . Radiotherapy schedule was 64Gy/32F with day 1 mitomycin C (12g/m2 ) and 5-fluorouracil (500mg/m2 /day) over days 1-5 and 22-26. Patients with T2-4aN0M0 urothelial cancer and a performance status (PS) of 0-1 were eligible. Prior neoadjuvant therapy was permitted. The phase I primary outcome was impact on radiotherapy treatment completion and toxicity experienced during treatment. The phase II primary outcome was local control at three-months post-treatment. ISRCTN identifier: 80733590. RESULTS: Between Sept-2012 and Oct-2016, 33 patients were recruited; 7 in phase I, 26 in phase II. Three patients in phase II were subsequently deemed ineligible and received no trial therapy. Eight patients discontinued cetuximab due to adverse effects. Median age of patients was 70.1 years (range 60.6-75.1), 20 were PS 0, 27 male and 26 had already received neoadjuvant chemotherapy. In phase I, all patients completed planned radiotherapy, with no delays or dose reductions. Of the 30 evaluable patients in phase II, 25 had confirmed local control 3-months post treatment (77%, 95% CI: 58-90). During the trial there were 18 serious adverse events. The study was halted due to slow accrual. CONCLUSION: Phase I data demonstrate it is feasible and safe to add cetuximab to chemoradiotherapy. Exploratory analysis of phase II data provides evidence to consider further clinical evaluation of cetuximab in this setting.
引用
- James ND, Liu W, Pirrie S, et al. TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer. BJU Int. 2022. PMID: 35908256. doi:10.1111/bju.15864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。